Search Videos and More
News
Dana-Farber Research News 07.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 16 - 30.
News
Three-Drug Treatment Shows Promise for Patients with Rare Blood Cancer BPDCN
A three-drug treatment combination led to high remission rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer, in a phase 2 clinical trial led by researchers at Dana-Farber Cancer Institute.
News
Dana-Farber Research Supports FDA Approval of New Therapy for “Double-Positive” Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with “double-positive” metastatic breast cancer based on results of the phase 3 PATINA study led by Otto Metzger, MD, Associate Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute.
News
Rapid Epigenetic Test Could Speed Diagnostics for Acute Leukemias
Acute leukemias are life-threatening blood conditions that need urgent treatment. Approved targeted therapies such as BCL2, IDH, and menin inhibitors have expanded treatment options for certain patients, but determining if a given patient might benefit from one of these treatments can take time. Doctors need to order multiple complex diagnostic workups that can take days or even weeks to complete.
News
Dana-Farber Research News 07.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 1 - 15.
Video
2026 ASCO Kidney Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates
Video
2026 ASCO Bladder Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates
Video
2026 ASCO Prostate Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates.
Video
ASCO26: David Reardon, MD, Glioblastoma Vaccine
Dana-Farber Cancer Institute's Dr. David Reardon reports on data showing a phase 1 trial looking at a personalized vaccine plus pembrolizumab sparked tumor-targeting T cells in glioblastoma and was linked to longer survival in immune responders.
Video
ASCO26: Sara Tolaney, MD, MPH, ASCENT-03
Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.
Video
ASCO26: Toni Choueiri, MD, KEYNOTE-654
Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.
Video
ASCO26: Jennifer Ligibel, MD, BWEL
Dana-Farber Cancer Institute's Dr. Jennifer Ligibel shared updated results from the BWEL study showing a weight loss intervention led to significantly better physical function, global physical and mental health, and symptom in patients with early breast cancer.